Recent Advances for Anti-Obesity Agents.
10.4093/jkd.2015.16.4.260
- Author:
Chul Sik KIM
1
Author Information
1. Division of Endocrinology and Metabolism, Department of Internal Medicine, Hallym University Sacred Heart Hospital, Anyang, Korea. ironeat@gmail.com
- Publication Type:Review
- Keywords:
Anti-obesity agents;
Obesity
- MeSH:
Anti-Obesity Agents*;
Behavior Therapy;
Cardiovascular Diseases;
Chronic Disease;
Food Habits;
Humans;
Life Style;
Obesity;
Risk Factors;
United States Food and Drug Administration;
Liraglutide
- From:Journal of Korean Diabetes
2015;16(4):260-268
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Obesity is one of the most significant risk factor for diabetes, cardiovascular disease, malignancy and other chronic diseases. The obesity and its associated conditions is one of the most urgent health concerns worldwide. Lifestyle modifications comprising diet modification, exercise, and behavior therapy are basic to the treatment for obesity. However, it has become apparent that lifestyle modifications alone will not be enough for many patients with obesity. Therefore, apractical approach includes consideration of pharmacotherapeutic options. Until 2012, orlistat was the only approved medication for long-term obesity management. In 2012, lorcaserin and phentermine/topiramate were approved by the USA Food and Drug Administration as new anti-obesity drugs, and in 2014, two additional medications were added, naltrexone/bupropion and liraglutide. This review discusses the different pharmacotherapeutic options for the treatment of obesity.
